Evidence map›Paper›PMID 34676285›Full record

ArticlePleura and peritoneum2021

A human

Dina Mönch, Jana Koch, Annika Maaß, Nicole Janssen, Thomas Mürdter, Philipp Renner, Petra Fallier-Becker, Wiebke Solaß, Matthias Schwab, Marc-H Dahlke and 2 more

Open access · diamondAbstract read
In one paragraph

Article in Pleura and peritoneum, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Dina MönchDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.ORCID https://orcid.org/0000-0002-2437-0394
Jana KochDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
Annika MaaßDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
Nicole JanssenDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
Thomas MürdterDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
Philipp RennerDepartment of General and Visceral Surgery, Robert-Bosch-Hospital, Stuttgart, Germany.
Petra Fallier-BeckerInstitute of Pathology, University of Tübingen, Tübingen, Germany.
Wiebke SolaßInstitute of Pathology, University of Tübingen, Tübingen, Germany.
Matthias SchwabDr. Margarete Fischer-Bosch Institute for Clinical Pharmacology, Stuttgart, Germany.
Marc-H DahlkeDepartment of General and Visceral Surgery, Robert-Bosch-Hospital, Stuttgart, Germany.
Hans J SchlittUniversity Medical Center Regensburg, Regensburg, Germany.
Tobias LeiboldDepartment of General and Visceral Surgery, Robert-Bosch-Hospital, Stuttgart, Germany.
Dr. Margarete Fischer-Bosch-Institute of Clinical Pharmacology · DERobert Bosch Hospital · DEUniversity of Tübingen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesPeritoneal metastasis (PM) is commonly observed in patients with colorectal cancer (CRC). The outcome of these patients is poor, with an average survival of only six months without therapy, which requires a better understanding of PM biology and new treatment strategies.

methodsWe established and characterized a human

resultsFresh human peritoneum was cultured for up to three weeks in a stainless steel ring system, allowing for survival of all peritoneal structures. Peritoneal cell survival was documented by light microscopy and immunohistochemical staining. Further, immunohistological characterization of the tissue revealed CD3-positive T-lymphocytes and vimentin-positive fibroblasts within the peritoneum. In addition, extracellular matrix components (collagens, matrix metalloproteinases) were localized within the tissue. Coculture with CRC cell lines and patient-derived CRC organoids revealed that cancer cells grew on the peritoneum and migrated into the tissue. Coculture with CRC cells confirmed that hyperthermal treatment at 41 °C for 90 min significantly enhanced the intracellular entry of doxorubicin. Moreover, treatment with mitomycin C under hyperthermic conditions significantly reduced the amount of cancer cells within the peritoneum.

conclusionsThis human

Indexed as

colorectal cancerex vivo modelHIPECperitoneal metastasisperitoneum

Identifiers

PMID34676285
PMCPMC8482451
OpenAlexW3185618580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.